Lipid

Clinical-stage biopharmaceutical firm CymaBay Therapeutics has received orphan drug designation from the US Food and Drug Administration (FDA) for its MBX-8025 to treat patients with hyperlipoproteinemia types I or V (Fredrickson classification).

Patients with types I and V hyperlipoproteinemias will have severely elevated levels of triglycerides in the blood.

MBX-8025 is a potent and selective peroxisome proliferator-activated receptor delta agonist of PPARd, a nuclear receptor important for lipid transport, storage and metabolism in liver and muscle.

CymaBay Therapeutics president and CEO Harold Van Wart said: "This second orphan drug designation is a validation of the company’s development strategy for MBX-8025 in which we are targeting indications with high unmet need and potentially expedited approval pathways.

"MBX-8025 potentially offers unique benefits for the treatment of metabolic disorders."

"MBX-8025 potentially offers unique benefits for the treatment of metabolic disorders, including HoFH, severe hypertriglyceridemia, primary biliary cirrhosis and nonalcoholic steatohepatitis.

"We remain on-track to initiate a Phase II pilot study of MBX-8025 in HoFH this quarter, and look forward to announcing further details regarding the expansion of our development strategy of MBX-8025 in the near-term."

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

According to the company, MBX-8025 demonstrated favourable effects on lipid and metabolic parameters in a Phase II study in patients with mixed dyslipidemia.

MBX-8025 helped in lowering of LDL-C with selective depletion of pro-atherogenic dense LDL-C particles and increased high density lipoprotein, as well as decreased triglycerides and cardiovascular inflammation biomarker hsCRP.

CymaBay has recently obtained FDA orphan drug designation for MBX-8025 to treat patients with homozygous familial hypercholesterolemia (HoFH).

The company plans to initiate a pilot clinical study to assess the activity of MBX-8025 in patients with HoFH.


Image: Hyperlipidaemia – lipid in EDTA tube. Photo: courtesy of Mark-shea.

Pharmaceutical Technology Excellence Awards - Have you nominated?

Nominations are now open for the prestigious Pharmaceutical Technology Excellence Awards - one of the industry's most recognised programmes celebrating innovation, leadership, and impact. This is your chance to showcase your achievements, highlight industry advancements, and gain global recognition. Don't miss the opportunity to be honoured among the best - submit your nomination today!

Nominate Now